PHI with Peritoneal carcinomatosis
How does this condition affect your private health insurance?
Bauchfellkarzinom, or peritoneal carcinomatosis, is the advanced spread of cancer to the peritoneum, the membrane lining the abdominal cavity and covering organs. It typically originates from primary tumors such as ovarian, colorectal, gastric, or appendiceal cancer. Symptoms often include abdominal pain, bloating, ascites (fluid accumulation), nausea, and unintended weight loss. Diagnosis involves imaging (CT, MRI), diagnostic laparoscopy, and biopsy. It indicates advanced disease, making treatment challenging. Management often includes systemic chemotherapy, targeted therapies, and in selected cases, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), aiming to prolong survival and improve quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms typically develop over several weeks to months. Initial diagnosis and staging can take several weeks.
Duration of Illness (Lifetime)
Chronic, progressive disease with a limited prognosis, often lasting months to a few years even with aggressive treatment. Not a one-time event.
Cost of Treatment (Initial)
High; initial diagnosis, extensive cytoreductive surgery, and specialized chemotherapy (e.g., HIPEC) can range from $50,000 to over $200,000 USD.
Cost of Treatment (Lifetime)
Very high; including multiple chemotherapy cycles, potential further surgeries, palliative care, and supportive therapies, lifetime costs can easily exceed $200,000 to over $1,000,000 USD.
Mortality Rate
High; prognosis is generally poor, with 5-year survival rates often ranging from 10% to 50% depending on primary origin and treatment, and much lower without aggressive therapy.
Risk of Secondary Damages
Very high; common physical complications include bowel obstruction, severe pain, malnutrition, ascites, and treatment-related toxicities. Significant psychological distress, anxiety, and depression are also very probable.
Probability of Full Recovery
Very low; peritoneal carcinomatosis represents advanced metastatic disease. While long-term remission is possible for a subset of highly selected patients, true complete recovery without recurrence is rare, typically less than 10%.
Underlying Disease Risk
100%; peritoneal carcinomatosis is always a metastatic spread from an underlying primary cancer (e.g., ovarian, colorectal, gastric, appendiceal, pancreatic).